CAJ | 학술논문

　　急性心肌梗死（acute myocardial infarction,AMI）是心内科的常发危重症，发病急，病情变化大，死亡率较高。随着近年来医疗科技水平的发展，AMI的诊断和治疗也进入了一个全新的阶段，新的诊断技术、介入治疗和静脉溶栓药物不断涌现，为争分夺秒再灌注治疗，提供了技术支撑和物质基础。本文并结合我国实际情况，对急性心肌梗死再灌注治疗在国内外的最新进展、策略现状进行一个系统全面的阐述。
　　급성심기경사（acute myocardial infarction,AMI）시심내과적상발위중증，발병급，병정변화대，사망솔교고。수착근년래의료과기수평적발전，AMI적진단화치료야진입료일개전신적계단，신적진단기술、개입치료화정맥용전약물불단용현，위쟁분탈초재관주치료，제공료기술지탱화물질기출。본문병결합아국실제정황，대급성심기경사재관주치료재국내외적최신진전、책략현상진행일개계통전면적천술。
acute myocardial infarction (acute myocardial infarction, AMI) is often in criticaly il patients in the Department of Cardiology, with rapid-onset, rapidly changing conditions, the mortality rate is higher. With the level of development of medical technology in recent years, the diagnosis and treatment of AMI also entered a new stage, new diagnostic techniques, interventional therapy and intravenous thrombolytic drugs are emerging,which has provided technical support and material basis for rapid reperfusion therapy. This article combined with China's actual situation, making a comprehensive exposition for the latest developments in the domestic and foreign policy and status quo of reperfusion therapy for acute myocardial infarction.